GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Molecular Determinants of Vascularization in Islets

$377,500
Vanderbilt University · R21 · FY2002 · DK

Smokeless Tobacco Cessation among American Indians Using in-Person Groups

$377,500
Christine Makosky Daley · University Of Kansas Medical Center · R01 · FY2016 · MD

Molecular Determinants of Vascularization in Islets

$377,500
Vanderbilt University · R21 · FY2003 · DK

Smokeless Tobacco Cessation among American Indians Using in-Person Groups

$377,500
Christine Makosky Daley · University Of Kansas Medical Center · R01 · FY2014 · MD

Smokeless Tobacco Cessation among American Indians Using in-Person Groups

$377,500
Christine Makosky Daley · University Of Kansas Medical Center · R01 · FY2015 · MD

(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.

$377,438
Marka Crittenden · Providence Portland Medical Center · R01 · FY2018 · CA

(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.

$377,438
Marka Crittenden · Providence Portland Medical Center · R01 · FY2016 · CA

(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.

$377,438
Marka Crittenden · Providence Portland Medical Center · R01 · FY2020 · CA

Rewiring the myeloid cell response to adjuvants to improve tumor control

$377,438
Michael James Gough · Providence Portland Medical Center · R01 · FY2021 · CA

Rewiring the myeloid cell response to adjuvants to improve tumor control

$377,438
Michael James Gough · Providence Portland Medical Center · R01 · FY2020 · CA

(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.

$377,438
Marka Crittenden · Providence Portland Medical Center · R01 · FY2017 · CA

Utilizing islet autoantibody signatures for precision medicine in type 2 diabetes

$377,436
Nisa M Maruthur · Johns Hopkins University · R01 · FY2024 · DK

Project 1: Employing CD11b-Agonists to Render PDAC Responsive to Immunotherapy

$377,428
David G Denardo · Washington University · P50 · FY2025 · CA

Genetic progression of pancreatic mucinous cystic neoplasms to invasive carcinoma

$377,251
Sunil R Hingorani · Fred Hutchinson Cancer Research Center · R01 · FY2009 · CA

Mechanistic Dissection of the Falconi Anemia Pathway of DNA Damage Response and Repair

$377,018
Patrick Sung · University Of Texas Hlth Science Center · R01 · FY2020 · CA

Mechanistic Dissection of the Falconi Anemia Pathway of DNA Damage Response and Repair

$377,018
Patrick Sung · University Of Texas Hlth Science Center · R01 · FY2021 · CA

Optimal Pairing of Chemotherapy with Immunotherapy for Pancreatic Cancer

$376,909
Peter A Cohen · Mayo Clinic Rochester · P50 · FY2016 · CA

Mechanistic investigations of microbiome-driven aryl hydrocarbon receptor activity and macrophage function in pancreatic cancer.

$376,878
Tracy L McGaha · University Health Network · R01 · FY2021 · CA

Multiplex FRET Imaging of Kinase-Epigenome Interregulations in Live Cancer Cells

$376,821
Yingxiao Wang · University Of California, San Diego · R33 · FY2017 · CA

Transcriptional Regulators of Exocrine Pancreatic Development

$376,800
Raymond J. Macdonald · Ut Southwestern Medical Center · R01 · FY2009 · DK

Tumor-intrinsic and paracrine roles of endoglin in pancreatic cancer

$376,732
Nam Y Lee · University Of Arizona · R01 · FY2023 · CA

Clinical study of GMCI in Pancreatic Cancer

$376,666
Estuardo Aguilar-Cordova · Advantagene, Inc · R43 · FY2007 · CA

Tansmission Electron Microscope for Analytical Micoscopy

$376,635
Gordon Livingston Todd · University Of Nebraska Medical Center · S10 · FY2009 · RR

Ultrasenstive vesicle analysis in precancerous pancreatic neoplasm (IPMN)

$376,614
Ralph Weissleder · Massachusetts General Hospital · R01 · FY2022 · CA

Ultrasenstive vesicle analysis in precancerous pancreatic neoplasm (IPMN)

$376,614
Ralph Weissleder · Massachusetts General Hospital · R01 · FY2023 · CA